Shanghai Pharma's Sotalol, Hydroxychloroquine secure key approvals, expanding market reach

Shanghai Pharmaceuticals Holding announced its subsidiary, Changzhou Pharmaceutical Factory, received approval for its Sotalol Hydrochloride Tablets to pass the generic drug consistency evaluation. This approval, effective December 16, 2025, enhances the drug's market competitiveness and its position in medical insurance and procurement. The company invested approximately CNY 4.6 million in the R&D for this evaluation.

Separately, Shanghai Pharma's subsidiary, Shanghai Sino-Western Pharmaceutical, secured a Philippine drug registration certificate for its Hydroxychloroquine Sulfate Tablets (200 mg), marking its approval for sale in the Philippines. This international expansion incurred approximately CNY 50,000 in registration fees.

The Sotalol Hydrochloride Tablets, used for various cardiac arrhythmias, generated RMB 33.117 million in Chinese hospital procurement in 2024. The Hydroxychloroquine Sulfate Tablets, used for rheumatoid arthritis and lupus, saw USD 4.13 million in sales in the Philippine market in 2024. Both approvals are expected to boost Shanghai Pharma’s market share and global competitiveness.